吸入布地奈德/福莫特罗治疗新型冠状病毒感染后咳嗽的疗效

doi:10.6040/j.issn.1671-7554.0.2023.0280

摘要/Abstract

摘要： 目的探讨吸入布地奈德/福莫特罗治疗新型冠状病毒感染后急性、亚急性咳嗽的有效性及安全性。方法回顾性收集2022年12月1日至2023年1月30日在山东第一医科大学附属省立医院呼吸与危重症医学科就诊,接受布地奈德/福莫特罗(160 μg/4.5 μg)治疗的新型冠状病毒感染后急性、亚急性咳嗽的患者资料。视觉模拟评分(VAS)评价咳嗽严重程度。结果共有168例患者纳入本研究,其中男73例,女95例,18~80岁,平均(47.02±15.13)岁;患者咳嗽时间5~60 d,平均(26.18±12.62)d。治疗总有效率为84.51%,患者平均治疗(5.29±2.45)d后,咳嗽症状明显好转;治疗后,VAS从(5.91±1.77)分降至(1.35±2.12)分(P<0.001)。纳入研究的患者中共有5例出现轻度不良反应(如声音嘶哑、头痛、心悸),不良反应率为2.98%,无严重不良反应发生。结论布地奈德/福莫特罗治疗新型冠状病毒感染后咳嗽的临床疗效显著,能快速缓解咳嗽症状,具有临床推广价值。

关键词: 新型冠状病毒感染, 急性咳嗽, 亚急性咳嗽, 布地奈德/福莫特罗, 治疗

Abstract: Objective To observe the efficacy and safety of Budesonide/Formoterol in the treatment of SARS-CoV-2-associated cough. Methods Clinical data of patients with acute or subacute cough after SARS-CoV-2 infection who received Budesonide/Formoterol(160 μg∶ 4.5 μg)during Dec. 1, 2022 and Jan. 30, 2023 were retrospectively analyzed. Severity of cough was evaluated with visual analogue scale(VAS). Results A total of 168 patients were involved, including 73 males and 95 females. The patients aged 18 to 80 years, average(47.02±15.13)years. Cough duration ranged from 5 to 60 days, average(26.18±12.62)days. The total effective rate of treatment was 84.51%, and the cough symptoms significantly improved after an average of(5.29±2.45)days of treatment. After treatment, the VAS score decreased from(5.91±1.77)to(1.35±2.12),(P<0.001). Mild adverse reactions such as voice hoarse, headache and palpitation occurred in 5 cases, with an adverse reaction rate of 2.98%. No serious adverse reactions occurred. Conclusion Budesonide/Formoterol has a significant clinical effect in the treatment of cough after SARS-CoV-2 infection and can quickly relieve cough symptoms, which has clinical application value.

Key words: SARS-CoV-2 infection, Acute cough, Subacute cough, Budesonide/Formoterol, Treatment

中图分类号:

R562.2+1

王骏仁,李道卫,王星光,姜淑娟. 吸入布地奈德/福莫特罗治疗新型冠状病毒感染后咳嗽的疗效[J]. 山东大学学报 (医学版), 2023, 61(8): 50-53.

WANG Junren, LI Daowei, WANG Xingguang, JIANG Shujuan. Clinical efficacy of Budesonide/Formoterol in the treatment of SARS-CoV-2-associated cough[J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 50-53.

参考文献

[1] 中华医学会呼吸病学分会哮喘学组. 咳嗽的诊断与治疗指南(2021)[J]. 中华结核和呼吸杂志, 2022, 45(1):13-46. Asthma Group of Chinese Thoracic Society. Chinese national guideline on diagnosis and management of cough(2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(1):13-46.
[2] Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome:role of viral neurotropism, neuroinflammation, and neuroimmune responses[J]. Lancet Respir Med, 2021, 9(5):533-544.
[3] Marquez C, Kerkhoff AD, Schrom J, et al. COVID-19 symptoms and duration of rapid antigen test positivity at a community testing and surveillance site during pre-delta, delta, and Omicron BA.1 periods[J]. JAMA Netw Open, 2022, 5(10):e2235844. doi:10.1001/jamanetworkopen.2022.35844.
[4] Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J]. Lancet, 2020, 395(10229):1054-1062.
[5] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance:a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335):1618-1624.
[6] Barry M, Althabit N, Akkielah L, et al. Clinical characteristics and outcomes of hospitalized COVID-19 patients in a MERS-CoV referral hospital during the peak of the pandemic[J]. Int J Infect Dis, 2021, 106:43-51. doi:10.1016/j.ijid.2021.03.058.
[7] Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK(PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial[J]. Lancet, 2021, 398(10303):843-855.
[8] Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19(STOIC): a phase 2, open-label, randomised controlled trial[J]. Lancet Respir Med, 2021, 9(7):763-772.
[9] Baker JR, Mahdi M, Nicolau DV Jr, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids:a mechanistic analysis[J]. Lancet Respir Med, 2022, 10(6):545-556.
[10] Lee TC, Bortolussi-Courval É, Belga S, et al. Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis[J]. Eur Respir J, 2022, 59(5):2102921. doi:10.1183/13993003.02921-2021.
[11] 中华医学会呼吸病学分会, 国家呼吸医学中心, 赖克方. 新型冠状病毒感染咳嗽的诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2023, 46(3):217-227. Chinese Thoracic Society, National Center for Respiratory Medicine, LAI Kefang. Expert consensus on the diagnosis and treatment of SARS-CoV-2-associated cough[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2023, 46(3):217-227.
[12] Sun JY, Zhan C, Deng Z, et al. Expression of interferon-γ and its effect on cough hypersensitivity in chronic refractory cough patients[J]. Thorax, 2022, 77(6):621-624.
[13] Deng Z, Zhou WL, Sun JY, et al. IFN-γ enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons[J]. Am J Respir Crit Care Med, 2018, 198(7):868-879.
[14] Deng Z, Ding WB, Li FY, et al. Pulmonary IFN-γ causes lymphocytic inflammation and cough hypersensitivity by increasing the number of IFN-γ-secreting T lymphocytes[J]. Allergy Asthma Immunol Res, 2022, 14(6):653-673.
[15] Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells[J]. J Virol, 2020, 95(1):e01648-e01620.
[16] Heinen N, Meister TL, Klöhn M, et al. Antiviral effect of budesonide against SARS-CoV-2[J]. Viruses, 2021, 13(7):1411. doi:10.3390/v13071411.
[17] Kim SR, Song JH, Ahn JH, et al. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation[J]. Antiviral Res, 2018, 151:87-96. doi:10.1016/j.antiviral.2018.01.012.
[18] Nicolau DV, Bafadhel M. Inhaled corticosteroids in virus pandemics:a treatment for COVID-19?[J]. Lancet Respir Med, 2020, 8(9):846-847.
[19] Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids[J]. Am J Respir Crit Care Med, 2020, 202(1):83-90.
[20] Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues[J]. Cell, 2020, 181(5):1016-1035.e19.
[21] Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon[J]. J Allergy Clin Immunol, 2021, 147(2):510-519.e5.
[22] Skevaki CL, Christodoulou I, Spyridaki IS, et al. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus[J]. Clin Exp Allergy, 2009, 39(11):1700-1710.
[23] Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells[J]. Respir Investig, 2020, 58(3):155-168.

相关文章 15

[1]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2]	孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62.
[3]	林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[4]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[5]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[6]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.
[7]	赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 ¹³¹I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28.
[8]	韩馨玮,牛月,魏代敏. 激素替代方案准备内膜的冻胚移植前雌激素治疗时间对新生儿体质量的影响[J]. 山东大学学报 (医学版), 2025, 63(11): 46-52.
[9]	黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[10]	薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19.
[11]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[12]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[13]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[14]	陈忠,王盛. 主动脉疾病治疗现状及思考[J]. 山东大学学报 (医学版), 2024, 62(9): 1-6.
[15]	范立彬,张鸿坤. 腹主动脉瘤腔内修复术后Ⅱ型内漏的预防及治疗进展[J]. 山东大学学报 (医学版), 2024, 62(9): 55-60.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed